| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 28 | 2018 | 91 | 4.790 |
Why?
|
| Liver | 11 | 2019 | 142 | 1.920 |
Why?
|
| Kidney Transplantation | 10 | 2021 | 114 | 1.800 |
Why?
|
| Living Donors | 10 | 2011 | 17 | 1.350 |
Why?
|
| Portal Vein | 7 | 2018 | 46 | 1.250 |
Why?
|
| Hepatectomy | 7 | 2018 | 61 | 1.160 |
Why?
|
| Carcinoma, Hepatocellular | 6 | 2021 | 25 | 1.130 |
Why?
|
| Liver Neoplasms | 6 | 2021 | 103 | 1.050 |
Why?
|
| Galactosyltransferases | 3 | 2013 | 3 | 0.740 |
Why?
|
| Liver Failure, Acute | 4 | 2018 | 5 | 0.740 |
Why?
|
| Humans | 55 | 2022 | 23331 | 0.640 |
Why?
|
| Transplantation, Heterologous | 3 | 2016 | 20 | 0.620 |
Why?
|
| Hepatomegaly | 1 | 2018 | 7 | 0.590 |
Why?
|
| Tissue Donors | 3 | 2021 | 63 | 0.540 |
Why?
|
| Kidney Failure, Chronic | 7 | 2020 | 123 | 0.530 |
Why?
|
| Swine | 8 | 2018 | 67 | 0.530 |
Why?
|
| Liver Regeneration | 4 | 2017 | 24 | 0.520 |
Why?
|
| Middle Aged | 29 | 2020 | 8055 | 0.510 |
Why?
|
| Male | 36 | 2021 | 12629 | 0.500 |
Why?
|
| Neuroendocrine Tumors | 3 | 2019 | 50 | 0.430 |
Why?
|
| Bile Ducts | 2 | 2011 | 4 | 0.410 |
Why?
|
| Female | 28 | 2021 | 13124 | 0.410 |
Why?
|
| Animals | 12 | 2021 | 3287 | 0.400 |
Why?
|
| BK Virus | 1 | 2013 | 12 | 0.400 |
Why?
|
| Constriction, Pathologic | 2 | 2019 | 27 | 0.400 |
Why?
|
| Retrospective Studies | 15 | 2022 | 3040 | 0.400 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2013 | 18 | 0.400 |
Why?
|
| Organ Preservation | 2 | 2011 | 6 | 0.390 |
Why?
|
| Perfusion | 2 | 2011 | 17 | 0.380 |
Why?
|
| Kidney Neoplasms | 1 | 2013 | 75 | 0.380 |
Why?
|
| Hypertension, Malignant | 1 | 2012 | 1 | 0.370 |
Why?
|
| Protein S Deficiency | 1 | 2011 | 2 | 0.370 |
Why?
|
| Hypercholesterolemia | 1 | 2011 | 20 | 0.360 |
Why?
|
| Organ Transplantation | 2 | 2021 | 32 | 0.360 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2022 | 22 | 0.350 |
Why?
|
| Mesentery | 1 | 2011 | 6 | 0.350 |
Why?
|
| Kidney | 4 | 2021 | 142 | 0.350 |
Why?
|
| Carcinoid Tumor | 1 | 2011 | 6 | 0.350 |
Why?
|
| Ligation | 4 | 2018 | 37 | 0.350 |
Why?
|
| Peritoneal Neoplasms | 1 | 2011 | 10 | 0.350 |
Why?
|
| Intestines | 1 | 2011 | 76 | 0.330 |
Why?
|
| Pancreas | 2 | 2021 | 30 | 0.330 |
Why?
|
| Decision Support Techniques | 1 | 2010 | 39 | 0.330 |
Why?
|
| Postoperative Complications | 9 | 2022 | 836 | 0.320 |
Why?
|
| Endothelial Cells | 1 | 2010 | 59 | 0.320 |
Why?
|
| Adrenal Cortex Neoplasms | 2 | 2020 | 14 | 0.320 |
Why?
|
| Treatment Outcome | 15 | 2022 | 2988 | 0.320 |
Why?
|
| Adrenocortical Carcinoma | 2 | 2020 | 15 | 0.320 |
Why?
|
| Pancreatic Neoplasms | 3 | 2019 | 88 | 0.310 |
Why?
|
| Food Hypersensitivity | 1 | 2009 | 40 | 0.300 |
Why?
|
| Bile Duct Neoplasms | 2 | 2005 | 4 | 0.290 |
Why?
|
| Hepatitis C | 2 | 2008 | 43 | 0.280 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2008 | 1 | 0.280 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2008 | 30 | 0.280 |
Why?
|
| Informed Consent | 2 | 2005 | 22 | 0.280 |
Why?
|
| Tissue and Organ Harvesting | 3 | 2004 | 14 | 0.280 |
Why?
|
| Time Factors | 7 | 2022 | 1289 | 0.270 |
Why?
|
| Neoplasm Staging | 4 | 2019 | 359 | 0.260 |
Why?
|
| Graft Survival | 8 | 2016 | 84 | 0.260 |
Why?
|
| Survival Rate | 6 | 2020 | 323 | 0.260 |
Why?
|
| Biliary Tract Diseases | 2 | 2019 | 3 | 0.250 |
Why?
|
| Tissue and Organ Procurement | 2 | 2003 | 30 | 0.250 |
Why?
|
| Coccidioides | 1 | 2006 | 3 | 0.250 |
Why?
|
| Coccidioidomycosis | 1 | 2006 | 8 | 0.240 |
Why?
|
| Registries | 1 | 2007 | 176 | 0.240 |
Why?
|
| Liver Diseases | 2 | 2017 | 33 | 0.240 |
Why?
|
| Adult | 13 | 2020 | 7070 | 0.230 |
Why?
|
| Directed Tissue Donation | 1 | 2005 | 1 | 0.230 |
Why?
|
| Donor Selection | 1 | 2005 | 1 | 0.230 |
Why?
|
| Physician-Patient Relations | 1 | 2005 | 38 | 0.220 |
Why?
|
| Hepatitis B, Chronic | 1 | 2003 | 2 | 0.210 |
Why?
|
| Incidence | 3 | 2021 | 636 | 0.210 |
Why?
|
| Communication | 1 | 2005 | 97 | 0.210 |
Why?
|
| Postoperative Hemorrhage | 2 | 2014 | 22 | 0.210 |
Why?
|
| Biliary Tract Surgical Procedures | 2 | 2019 | 3 | 0.210 |
Why?
|
| Papio hamadryas | 2 | 2013 | 2 | 0.200 |
Why?
|
| Swine, Miniature | 2 | 2013 | 6 | 0.200 |
Why?
|
| Venous Thrombosis | 2 | 2019 | 42 | 0.200 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 1441 | 0.190 |
Why?
|
| Liver Failure | 2 | 2018 | 10 | 0.190 |
Why?
|
| Aneurysm | 1 | 2022 | 10 | 0.190 |
Why?
|
| Arteriovenous Fistula | 1 | 2022 | 10 | 0.190 |
Why?
|
| Gastroparesis | 1 | 2022 | 3 | 0.190 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2022 | 10 | 0.190 |
Why?
|
| Hospitals, University | 1 | 2001 | 23 | 0.180 |
Why?
|
| Urogenital Abnormalities | 1 | 2021 | 7 | 0.180 |
Why?
|
| Specialization | 1 | 2001 | 12 | 0.180 |
Why?
|
| Immunoglobulin G | 2 | 2013 | 70 | 0.180 |
Why?
|
| Pancreas Transplantation | 1 | 2021 | 17 | 0.180 |
Why?
|
| Infertility, Female | 1 | 2021 | 21 | 0.180 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 12 | 0.180 |
Why?
|
| Organ Size | 2 | 2018 | 84 | 0.180 |
Why?
|
| Random Allocation | 2 | 2018 | 105 | 0.180 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 198 | 0.180 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 21 | 0.180 |
Why?
|
| Transplant Recipients | 1 | 2021 | 21 | 0.180 |
Why?
|
| Renal Dialysis | 4 | 2022 | 82 | 0.170 |
Why?
|
| Bone Marrow Transplantation | 2 | 2013 | 19 | 0.170 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 53 | 0.170 |
Why?
|
| Prognosis | 4 | 2020 | 740 | 0.170 |
Why?
|
| Ultrasonography | 3 | 2018 | 204 | 0.170 |
Why?
|
| Surgical Instruments | 1 | 2020 | 24 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 113 | 0.170 |
Why?
|
| Health Care Costs | 1 | 2020 | 61 | 0.160 |
Why?
|
| Suture Techniques | 1 | 2020 | 105 | 0.160 |
Why?
|
| Hepatic Veins | 2 | 2018 | 10 | 0.160 |
Why?
|
| Margins of Excision | 1 | 2020 | 29 | 0.160 |
Why?
|
| Adrenalectomy | 1 | 2019 | 5 | 0.160 |
Why?
|
| Jejunostomy | 1 | 2019 | 8 | 0.160 |
Why?
|
| Pancreatectomy | 1 | 2019 | 11 | 0.160 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 82 | 0.160 |
Why?
|
| Aged | 11 | 2020 | 7552 | 0.150 |
Why?
|
| Patient Compliance | 1 | 2020 | 145 | 0.150 |
Why?
|
| Abdominal Neoplasms | 1 | 2019 | 16 | 0.150 |
Why?
|
| Child, Preschool | 2 | 2013 | 578 | 0.150 |
Why?
|
| Heat Stroke | 1 | 2018 | 1 | 0.150 |
Why?
|
| Intestinal Neoplasms | 1 | 2018 | 12 | 0.150 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2018 | 24 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 98 | 0.140 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 35 | 0.140 |
Why?
|
| Papio | 3 | 2016 | 7 | 0.140 |
Why?
|
| Stomach Neoplasms | 1 | 2018 | 32 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 43 | 0.140 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 57 | 0.140 |
Why?
|
| Hypertrophy | 1 | 2017 | 22 | 0.140 |
Why?
|
| Neovascularization, Physiologic | 1 | 2017 | 22 | 0.130 |
Why?
|
| Vascular Patency | 4 | 2022 | 17 | 0.130 |
Why?
|
| Patient Selection | 4 | 2019 | 171 | 0.130 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 91 | 0.130 |
Why?
|
| Gene Knockout Techniques | 2 | 2013 | 9 | 0.120 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 517 | 0.120 |
Why?
|
| Thrombocytopenia | 2 | 2014 | 21 | 0.120 |
Why?
|
| Liver Cirrhosis | 2 | 2014 | 44 | 0.120 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2022 | 19 | 0.120 |
Why?
|
| Liver Function Tests | 2 | 2015 | 21 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 169 | 0.120 |
Why?
|
| Tobacco Use Disorder | 1 | 2015 | 18 | 0.120 |
Why?
|
| Jaundice, Obstructive | 1 | 2015 | 1 | 0.120 |
Why?
|
| Biopsy | 2 | 2013 | 192 | 0.110 |
Why?
|
| Cysts | 1 | 2015 | 14 | 0.110 |
Why?
|
| Graft Rejection | 4 | 2020 | 61 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2015 | 880 | 0.110 |
Why?
|
| Antibodies, Heterophile | 1 | 2013 | 1 | 0.110 |
Why?
|
| Heterografts | 1 | 2013 | 16 | 0.100 |
Why?
|
| Heart Transplantation | 1 | 2014 | 29 | 0.100 |
Why?
|
| Heart-Assist Devices | 1 | 2014 | 18 | 0.100 |
Why?
|
| Creatinine | 1 | 2013 | 40 | 0.100 |
Why?
|
| Bilirubin | 2 | 2011 | 11 | 0.100 |
Why?
|
| Hypoxia | 2 | 2017 | 30 | 0.100 |
Why?
|
| Hematoma | 1 | 2013 | 18 | 0.100 |
Why?
|
| Ureterostomy | 1 | 2012 | 1 | 0.100 |
Why?
|
| Polytetrafluoroethylene | 2 | 2011 | 5 | 0.100 |
Why?
|
| Cystostomy | 1 | 2012 | 5 | 0.100 |
Why?
|
| Blood Vessel Prosthesis | 2 | 2011 | 13 | 0.090 |
Why?
|
| Databases, Factual | 3 | 2019 | 314 | 0.090 |
Why?
|
| Ureter | 1 | 2012 | 27 | 0.090 |
Why?
|
| Hepatic Encephalopathy | 1 | 2012 | 3 | 0.090 |
Why?
|
| Protein S | 1 | 2011 | 1 | 0.090 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 102 | 0.090 |
Why?
|
| Intracranial Pressure | 1 | 2012 | 11 | 0.090 |
Why?
|
| Warm Ischemia | 1 | 2011 | 2 | 0.090 |
Why?
|
| Bile | 1 | 2011 | 4 | 0.090 |
Why?
|
| Intracranial Hypertension | 1 | 2012 | 12 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 593 | 0.090 |
Why?
|
| Alkaline Phosphatase | 1 | 2011 | 18 | 0.090 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2011 | 5 | 0.090 |
Why?
|
| Monitoring, Intraoperative | 1 | 2012 | 36 | 0.090 |
Why?
|
| Hemodynamics | 1 | 2011 | 62 | 0.090 |
Why?
|
| Energy Metabolism | 1 | 2011 | 42 | 0.090 |
Why?
|
| Oxygen | 1 | 2011 | 58 | 0.090 |
Why?
|
| Endoscopy, Digestive System | 1 | 2011 | 8 | 0.090 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2011 | 20 | 0.090 |
Why?
|
| Intestinal Obstruction | 1 | 2011 | 11 | 0.090 |
Why?
|
| Waiting Lists | 2 | 2014 | 18 | 0.090 |
Why?
|
| Transplantation, Autologous | 1 | 2011 | 98 | 0.080 |
Why?
|
| Risk Factors | 3 | 2022 | 1998 | 0.080 |
Why?
|
| End Stage Liver Disease | 1 | 2010 | 11 | 0.080 |
Why?
|
| Complement C3a | 1 | 2010 | 1 | 0.080 |
Why?
|
| Complement Activation | 1 | 2010 | 5 | 0.080 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2010 | 15 | 0.080 |
Why?
|
| Immunoglobulin M | 1 | 2010 | 12 | 0.080 |
Why?
|
| Tissue Engineering | 1 | 2010 | 25 | 0.080 |
Why?
|
| Young Adult | 2 | 2020 | 1674 | 0.080 |
Why?
|
| United States | 3 | 2020 | 1829 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2009 | 51 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2018 | 245 | 0.080 |
Why?
|
| Anaphylaxis | 1 | 2009 | 11 | 0.080 |
Why?
|
| Nephrectomy | 1 | 2009 | 37 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 203 | 0.080 |
Why?
|
| Hemophilia A | 1 | 2008 | 49 | 0.070 |
Why?
|
| Cadaver | 1 | 2009 | 275 | 0.070 |
Why?
|
| Reoperation | 1 | 2012 | 776 | 0.070 |
Why?
|
| Transplantation Chimera | 1 | 2008 | 2 | 0.070 |
Why?
|
| Transplantation Tolerance | 1 | 2008 | 4 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 289 | 0.070 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 113 | 0.070 |
Why?
|
| Colonoscopy | 1 | 2008 | 71 | 0.070 |
Why?
|
| Rats, Wistar | 2 | 2017 | 54 | 0.070 |
Why?
|
| New England | 1 | 2006 | 2 | 0.060 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2006 | 3 | 0.060 |
Why?
|
| Postoperative Period | 2 | 2019 | 243 | 0.060 |
Why?
|
| Blood Coagulation Factors | 2 | 2016 | 19 | 0.060 |
Why?
|
| Hepatoblastoma | 1 | 2005 | 1 | 0.060 |
Why?
|
| Cholangiocarcinoma | 1 | 2005 | 3 | 0.060 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2005 | 5 | 0.060 |
Why?
|
| Cystic Duct | 1 | 2005 | 1 | 0.060 |
Why?
|
| Coercion | 1 | 2005 | 4 | 0.060 |
Why?
|
| Cholestasis | 1 | 2005 | 7 | 0.060 |
Why?
|
| Social Values | 1 | 2005 | 10 | 0.060 |
Why?
|
| Interview, Psychological | 1 | 2005 | 39 | 0.060 |
Why?
|
| Medical Oncology | 1 | 2005 | 43 | 0.060 |
Why?
|
| Liver Circulation | 2 | 2017 | 5 | 0.050 |
Why?
|
| Animals, Genetically Modified | 2 | 2014 | 17 | 0.050 |
Why?
|
| Contrast Media | 1 | 2004 | 60 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2005 | 81 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 296 | 0.050 |
Why?
|
| Adenoma | 1 | 2005 | 61 | 0.050 |
Why?
|
| Anastomosis, Surgical | 2 | 2019 | 27 | 0.050 |
Why?
|
| Decision Making | 1 | 2005 | 187 | 0.050 |
Why?
|
| Pancreatic Fistula | 1 | 2022 | 1 | 0.050 |
Why?
|
| Rats | 2 | 2016 | 625 | 0.050 |
Why?
|
| Strategic Planning | 1 | 2021 | 7 | 0.050 |
Why?
|
| Steroids | 1 | 2022 | 22 | 0.050 |
Why?
|
| Uterus | 1 | 2021 | 17 | 0.050 |
Why?
|
| Hysterectomy | 1 | 2021 | 25 | 0.050 |
Why?
|
| Benzofurans | 1 | 2021 | 5 | 0.040 |
Why?
|
| Naphthoquinones | 1 | 2021 | 5 | 0.040 |
Why?
|
| Aniline Compounds | 1 | 2021 | 29 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2021 | 45 | 0.040 |
Why?
|
| Cost Savings | 1 | 2020 | 28 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2022 | 127 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 109 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2013 | 322 | 0.040 |
Why?
|
| Mitotane | 1 | 2019 | 4 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2019 | 24 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 87 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 171 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 43 | 0.040 |
Why?
|
| Adolescent | 2 | 2020 | 1916 | 0.040 |
Why?
|
| Blood Coagulation Disorders | 1 | 2019 | 13 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2019 | 22 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 274 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 82 | 0.040 |
Why?
|
| Brain | 1 | 2006 | 1200 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2019 | 85 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 240 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 324 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2017 | 15 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 246 | 0.030 |
Why?
|
| Portal Pressure | 1 | 2017 | 4 | 0.030 |
Why?
|
| Mice | 1 | 2021 | 1236 | 0.030 |
Why?
|
| Hyperplasia | 1 | 2017 | 19 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2016 | 8 | 0.030 |
Why?
|
| Models, Animal | 1 | 2016 | 100 | 0.030 |
Why?
|
| Chicago | 1 | 2018 | 819 | 0.030 |
Why?
|
| Policy | 1 | 2015 | 8 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 291 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 565 | 0.030 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2015 | 6 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2015 | 45 | 0.030 |
Why?
|
| Stents | 1 | 2015 | 77 | 0.030 |
Why?
|
| Smoking | 1 | 2015 | 168 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2014 | 58 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 1429 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 140 | 0.030 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2013 | 4 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2013 | 34 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 3783 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 487 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 1038 | 0.020 |
Why?
|
| Biocompatible Materials | 1 | 2011 | 83 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2010 | 10 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2010 | 48 | 0.020 |
Why?
|
| Angiography | 1 | 2009 | 25 | 0.020 |
Why?
|
| Factor VIII | 1 | 2008 | 32 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 2008 | 54 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2008 | 73 | 0.020 |
Why?
|
| Hepatitis C, Chronic | 1 | 2008 | 42 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2008 | 1 | 0.020 |
Why?
|
| Transplantation Immunology | 1 | 2008 | 2 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2008 | 2 | 0.020 |
Why?
|
| Granzymes | 1 | 2008 | 7 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2008 | 38 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 95 | 0.020 |
Why?
|
| Laparoscopy | 1 | 2009 | 183 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2008 | 195 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2008 | 285 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2011 | 1523 | 0.020 |
Why?
|
| Vena Cava, Inferior | 1 | 2006 | 9 | 0.020 |
Why?
|
| Syndrome | 1 | 2005 | 70 | 0.010 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2004 | 2 | 0.010 |
Why?
|
| Biliary Tract | 1 | 2004 | 3 | 0.010 |
Why?
|
| Hepatic Artery | 1 | 2004 | 3 | 0.010 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2004 | 27 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2004 | 112 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2004 | 158 | 0.010 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2002 | 5 | 0.010 |
Why?
|
| Forecasting | 1 | 2001 | 82 | 0.010 |
Why?
|